Study Protocol: The Efficacy of Mushroom to Reduce Cognitive Decline in At-Risk Middle-aged Adults and Young-olds Living in the Community
1 other identifier
interventional
600
1 country
1
Brief Summary
The investigator's objective is to explore the definitive evidence of mushroom on cognitive functions among at-risk middle-aged and young-olds. The investigator carefully designed a randomized controlled trial (RCT) to assess the role of mushrooms in promoting cognitive functioning among around 600 middle-aged adults and young-olds. Participants were selected based on specific inclusion criteria, such as being community-living adults aged 45-80 years with a family history of dementia or subjective cognitive decline, while consuming mushrooms no more than once a week and having no dementia, along with the exclusion of individuals with neurological or psychiatric disorders and significant sensory or motor impairments. Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2026
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 21, 2026
CompletedFirst Posted
Study publicly available on registry
August 20, 2026
CompletedStudy Start
First participant enrolled
October 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
September 1, 2026
April 1, 2026
2.2 years
July 21, 2026
August 28, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
MMSE
Total scores change
24 months
Secondary Outcomes (7)
plasma ergothioneine
24 months
Rey Auditory Verbal Learning Test
12, and 24 months
inflammatory markers
24 months
NfL
24 months
Epigenetic age
24 months
- +2 more secondary outcomes
Study Arms (2)
mushroom powder intervention arm
EXPERIMENTALPlacebo arm
NO INTERVENTIONInterventions
Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance monitored using electronic diary apps. The powder contains 7.0 mg/g of ergothioneine (dry weight).
Eligibility Criteria
You may qualify if:
- (1) Community-living adult aged 45 years to 80 years, AND
- (2) Family history of Alzheimer's disease or having subjective cognitive (SCD) defined as "self-reported memory problems that have been getting worse over the past year.", AND
- (3) Consume mushrooms no more than once a week, AND
- (4) No dementia: CDR global score equal to zero.
You may not qualify if:
- (1) Any diagnosis of neurological diseases (e.g., epilepsy, stroke) made by a clinician, OR
- (2) Any diagnosis of psychiatric illnesses (e.g., depressive disorders) made by a clinician, OR
- (3) Significant sensory or motor impairments, OR
- (4) Known allergy to mushrooms or a history of serious food allergies, OR
- (5) Participants with a history of gout, OR
- (6) Diagnosed with hyperuricemia.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tahir Foundation Building, MD1, Level 12 (12 Science Drive 2)
Singapore, 117549, Singapore
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lei FEng
National University of Singapore
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
July 21, 2026
First Posted
August 20, 2026
Study Start
October 1, 2026
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2030
Last Updated
September 1, 2026
Record last verified: 2026-04